TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00623285
Drug: Placebo/Lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo orally,60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive placebo twice a day through the first 2 post-operative days for a total of six doses. If the patient is unable to swallow and NG tube is in place, the medication can be dissolved in water and administered through the NG tube.
Study: NCT01328496
Drug: Preparative Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (75 mg/m2), fractionated total body irradiation (TBI) (12.0 Gy), and cyclophosphamide (120mg/kg) with mesna. Fludarabine will be given once a day at 25 mg/m2 for three days on day -10 to day -8, TBI will be given twice a day at 150 cGy for four days on day -7 to day -4, and cyclophosphamide will be given once a day for at 60mg/kg for two days on day -3 and day -2.~Post-transplantation immunosuppression with cyclosporine and MMF will begin on day -3. Cord Blood infusion will occur on day 0 and G-CSF will start on day +1.
Study: NCT01691053
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg once daily
Study: NCT01691053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02641314
Drug: metronomic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Propranolol 0.5 mg/kgxd p.o. day 1,~  1. mg/kgxd p.o. day 2,~ 2. mg/kgxd p.o. day 3-365 (maximum total daily dose: 120 mg) divided in 2 doses per day~* Celecoxib 400 mg/m2xd p.o.; day 1-365 (maximum total daily dose: 800 mg) divided in 2 doses per day~* Cyclophosphamide cycle 1, day1: loading dose: 500 mg/m2 intravenous 1-h-infusion, single dose day 2-365 25 mg/m2xd p.o (maximum total daily dose: 50 mg) as single daily dose~* Vinblastine 3 mg/m2xd i.v. (maximum total daily dose: 6 mg) administered day 1 and 15 (every two weeks) as single daily dose~* Etoposide 25 mg/m2xd p.o.; day 1-21 weeks 1-3, 9-11, 17-19, 25-27 (maximum total daily dose: 50 mg) as single daily dose
Study: NCT01637818
Drug: Opiate
Normalized name: Squill opiate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative pain therapy
Study: NCT01637818
Drug: non-steroidal anti-inflammatory drug
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative pain therapy
Study: NCT02204033
Drug: 186 Re - labelled hMAb BIWA 4
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02204033
Drug: unlabelled hMAb BIWA 4 - medium dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04952051
Drug: Enalapril Folic Acid Tablets Combined With amlodipine
Normalized name: enalapril / felodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril Folic Acid Tablets 10.8mg Combined With amlodipine 5 or 10mg
Study: NCT03990090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00002707
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 IV every 21 days for 4 cycles
Study: NCT00002707
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2 IV every 21 days fo 4 cycles
Study: NCT04328012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered 14 days
Study: NCT03673956
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 240mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
Study: NCT02220361
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: received 20 ml intravenous physiological saline The infusion were completed in 30 minutes.
Study: NCT02578472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo will be administered orally.
Study: NCT00650598
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valdecoxib 40 mg (two 20-mg tablets) loading dose by mouth on Day 1 followed by 20 mg twice daily (BID) on Days 2-6
Study: NCT00650598
Drug: diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac sodium delayed release tablets 75 mg by mouth twice daily (BID) for 6 days
Study: NCT00395213
Drug: Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with SSRIs or SNRIs
Study: NCT03854851
Drug: Naldebain
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Naldebain group, patients will be injected with Naldebain (150 mg/2 ml, IM injection) between 12 and 24 hours prior to surgery.
Study: NCT03854851
Drug: Morpine
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Morphine group, patients will receive morphine as needed after surgery.
Study: NCT02593968
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02147509
Drug: 0.02% Fm, SH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sjogren's Syndrome patients with severe dry eye
Study: NCT02147509
Drug: 0.02% Fm, SH, 0.05% CsA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sjogren's Syndrome patients with severe dry eye
Study: NCT02147509
Drug: 0.02% Fm, SH, AS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sjogren's Syndrome patients with severe dry eye
Study: NCT01488409
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg by mouth (PO) three times daily
Study: NCT00705159
Drug: loteprednol etabonate and tobramycin
Normalized name: Loteprednol Etabonate and Tobramycin Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular administration of loteprednol etabonate and tobramycin 4 times per day (QID) for 14 days.
Study: NCT03028285
Drug: arginine sodium succinate
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at 3 different combinations of dose and infusion rate under the close monitoring of vital signs and other safety parameters.
Study: NCT00705159
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical ocular administration of Tobramycin QID for 14 days.
Study: NCT00859807
Drug: Flavoquine®, Camoquin® Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
Study: NCT00993304
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the first 3-week period, the treatment will be with placebo. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg of liraglutide. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
Study: NCT01192204
Drug: 10% FBR containing bioadhesive gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
Study: NCT01313884
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose 75 mg/m2 to a maximum of 450mg/m2
Study: NCT03044652
Drug: Estriol Cream 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g of the reference product Estriol Cream 0.1% will be applied intravaginally once daily in the evening for the first 3 weeks. Subsequently, the frequency will be reduced to twice a week for the last 3 weeks for all patients in this treatment group.
Study: NCT01542255
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/m2 cyclophosphamide taken orally every day for 3 weeks with one week rest
Study: NCT02077803
Drug: CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 2, to be taken orally.
Study: NCT01180764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching active lovaza, 1 g capsules, 4 capsules po daily
Study: NCT03228498
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo b.i.d plus Nimodipine 30 mg t.i.d
Study: NCT01928082
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 weeks of Vivelle-Dot 0.05 mg/day followed by 4 weeks of Vivelle-Dot 0.10 mg/day
Study: NCT03511820
Drug: Lipo-AB® (amphotericin B) liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Name: Lipo-AB® (amphotericin B) liposome for injection~2. Dosage form: Lyophilized powder 50 mg/vial~3. Dose: Based on approved package insert and physician's discretion Recommended initial dose: 3 mg/kg/day~4. Dosing schedule:~All patients will receive Lipo-AB® based on the approved package insert and physician's clinical decision.
Study: NCT00546234
Drug: long acting beta agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turbohaler, 6 \& 12 mcg
Study: NCT00744848
Drug: SKY0402
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration 300 mg SKY0402 in a 40-mL injection volume
Study: NCT03947567
Drug: Recombinant Human Coagulation FVIII
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received SCT800 for prophylaxis and/or on-demand treatment for 120 weeks.
Study: NCT03148756
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
Study: NCT04101578
Drug: Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment regimens are determined according to the physician's judgment and preferences of the patients.
Study: NCT05567393
Drug: TAK-951 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-951 placebo-matching SC injection
Study: NCT03734562
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone or sotalol therapy
Study: NCT00314080
Drug: Botulinum AntiToxin
Normalized name: Botulinum antitoxin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01690104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01270958
Drug: Avamys aqueous nasal spray 110mcg
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the visit 1, subjects who fulfill the inclusion criteria are eligible to be included in the group to self-administer intranasal treatment of fluticasone furoate aqueous nasal spray 110 mcg once daily for 6 week. The subjects are instructed to administer two sprays from the device into each nostril once daily every morning. Administration of the dose will be performed by alternately spraying one spray to each nostril followed by a second spray to each nostril. Subjects will not be permitted to take any anti-allergy or rhinitis medication during the screening or treatment period.~Throughout the study, subjects will document their study drug administration/compliance, any medical conditions experienced, and any concomitant medications taken.
Study: NCT01256203
Drug: Solar Protection Formula SPF® 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solar Protection Formula SPF® 60 (2 mg/cm²) will be topically applied on a randomly predetermined specific skin area on the back of each subject on four separate occasions over 3 months. The same skin area will never be exposed more than once to the sunscreen.
Study: NCT01619163
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01619163
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low dose, 7.5 mg/day
Study: NCT02322099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic alendronate 70 mg tablet administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART
Study: NCT01601470
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 400mg QD was administered alone for 4 days and in combination with sildenafil for 1 day
Study: NCT04129086
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
Study: NCT03513250
Drug: hyoscine-n-butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.
Study: NCT03513250
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: an equal volume(1 ml ) of normal saline will be administered before the end of cesarean section.
Study: NCT01160861
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeating ascending dose
Study: NCT02223429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
Study: NCT02726126
Drug: Comparative study between transdermal fentanyl and melatonin patches on postoperative pain relief after lumber laminectomy
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02420795
Drug: Akt/ERK Inhibitor ONC201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00587444
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300u/kg of heparin for CPB ACT performed. If ACT is \< 480 seconds a bolus of 5000u heparin will be given. ACT will be repeated and bolus given until ACT is\>480 seconds
Study: NCT00003691
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01293006
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet matching suvorexant, orally, once daily, for 4 consecutive days
Study: NCT03201848
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given to subject will be adjusted by body weight (\<10kg, Placebo given to subject will be adjusted by body weight(\<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day;) .
Study: NCT03201848
Drug: Huaiqihuang Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huaiqihuang Granule given to subject will be adjusted by body weight (\<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day)
Study: NCT02759562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via subcutaneous injection
Study: NCT01945268
Drug: inactivated trivalent influenza vaccine
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml dose injected intramuscularly
Study: NCT03948451
Drug: [14C]AZD5718 Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg dose of \[14C\]AZD5718 Oral Suspension
Study: NCT03101527
Drug: Omega-3 PUFA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g docosahexaenoic daily for the duration of the study
Study: NCT03029676
Drug: opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: analgetic, sedative
Study: NCT00550277
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBHLBH589 will be administered orally at a dose of 45 mg (1 - 5 mg capsule and 2 - 20 mg capsules) on Monday and Thursday of each week (twice weekly). To enable patients to undergo cardiac monitoring (Section 3.5.2), all patients must begin treatment on a Monday, and continue Monday/Thursday dosing during subsequent treatment cycles.
Study: NCT02293824
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given per standard of care.
Study: NCT00703170
Drug: Pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04503850
Drug: Alpha Blockers
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha blocker daily and evaluation of erectile function using international index of erectile function 5 scoring system
Study: NCT01925391
Drug: Tono-pen XL Applanation tonometer + Ocu-film +
Normalized name: dexamethasone phosphate Ophthalmic Solution [Ocu-Dex]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01362699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form=tablet, route=oral administration. One tablet once daily for 7 days.
Study: NCT01765946
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03954990
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets
Study: NCT03954379
Drug: Standard of Care (ACB, SA, peri-op pain management)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INTERVENTION BEFORE SURGERY~Adductor Canal Block will be done using Adductor canal catheter (tube in the thigh) + injection of freezing medication~INTERVENTION DURING SURGERY~IV propofol for sedation~INTERVENTION AFTER SURGERY~Injection of salty water through the tube in the thigh x 2
Study: NCT03954379
Drug: IPACK and multi-modal analgesic regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: INTERVENTION BEFORE SURGERY~1. Adductor Canal Block will be done using Adductor canal catheter (tube in the thigh) + injection of freezing medication~2. iPACK block ( infiltration between Popliteal Artery and posterior Capsule of the Knee) - injection of freezing medication in the back of the knee~INTERVENTION DURING SURGERY~1. IV dexmedetomidine~2. IV ketamine Both for sedation~INTERVENTION AFTER SURGERY~1. injection of freezing medication through the tube in the thigh x 2~2. IV dexamethasone 8 mg 1 day after surgery
Study: NCT00000361
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000361
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00294684
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule and dosing of corticosteroids following portoenterostomy in infants with biliary atresia are listed below.~Days 1-3: Methylprednisolone, IV-4mg/kg/day, divided BID Days 4-7: Prednisolone, PO-4mg/kg/day, divided BID Week 2: 4 mg/kg/day, divided BID Week 3: 2 mg/kg/day, divided BID Week 4: 2 mg/kg/day, divided BID Week 5: 1 mg/kg/day, once a day Week 6: 1 mg/kg/day, once a day Week 7: 0.8 mg/kg/day, once a day Week 8: 0.6 mg/kg/day, once a day Week 9: 0.4 mg/kg/day, once a day Week 10: 0.2 mg/kg/day, once a day Week 11: 0.1 mg/kg/day, once a day Week 12-13: 0.1 mg/kg/day, every other day Week 14: Stop
Study: NCT00294684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule and dosing of placebo following portoenterostomy in infants with biliary atresia:~Days 1-3: IV - normal saline 4 mg/kg/day, divided BID Days 4-7: PO placebo 4 mg/kg/day, divided BID Week 2: PO placebo 4 mg/kg/day, divided BID Week 3: PO placebo 2 mg/kg/day, divided BID Week 4: PO placebo 2 mg/kg/day, divided BID Week 5: PO placebo 1 mg/kg/day, once a day Week 6: PO placebo 1 mg/kg/day, once a day Week 7: PO placebo 0.8 mg/kg/day, once a day Week 8: PO placebo 0.6 mg/kg/day, once a day Week 9: PO placebo 0.4 mg/kg/day, once a day Week 10: PO placebo 0.2 mg/kg/day, once a day Week 11: PO placebo 0.1 mg/kg/day, once a day Week 12-13: PO placebo 0.1 mg/kg/day, once a day every other day Week 14: Stop
Study: NCT03168555
Drug: chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1250 mg CDCA is given with a study meal
Study: NCT04362813
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
Study: NCT03528824
Drug: Diclofenac Gel
Normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily application of diclofenac gel, 4 weeks application
Study: NCT04144049
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.
Study: NCT00778713
Drug: Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01539811
Drug: Long course antibiotics
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long course (\>2 weeks) of antibiotics will be prescribed
Study: NCT01265342
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nebulised suspension twice a day for 10 days
Study: NCT01938001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical matched capsule) PO daily on Days 1 to 21 every 28 days
Study: NCT00110474
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00110474
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04003181
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin or Rifaximin for 10 days.
Study: NCT04003181
Drug: Bile Acid Binder
Normalized name: bile salts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine or Colesevelam lifelong.
Study: NCT05007223
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg/day for 28 days(Given doxycycline to patients with Hailey-Hailey disease)
Study: NCT04281017
Drug: Balanced anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg